Addendum
Benralizumab (asthma) - Addendum to Commission A18-11
Report documents
-
Addendum
Benralizumab (asthma) - Addendum to Commission A18-11
Dossier assessment
Indication:
Add-on maintenance treatment in adults with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting beta agonists
Result of dossier assessment:
Conclusion of dossier assessment A18-11 unchanged
Additional information
Federal Joint Committee (G-BA)
2018-08-02 A G-BA decision was published.
Project details
- Project no.
- A18-42
- Commission
- Commission awarded on 26.06.2018 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Airways and respiratory system
- Note
-
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Connected Projects
-
Dossier assessment
Benralizumab (asthma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed